<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zinc acetate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zinc acetate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zinc acetate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12333" href="/d/html/12333.html" rel="external">see "Zinc acetate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="88572" href="/d/html/88572.html" rel="external">see "Zinc acetate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9831430"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Galzin;</li>
<li>Wilzin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9850296"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Chelating Agent, Oral</li></ul></div>
<div class="block doa drugH1Div" id="F9850339"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="356294e9-9c29-43ce-b91c-44f10819a66f">Wilson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease: </b>
<b>Note:</b> Dose expressed in mg elemental zinc:</p>
<p style="text-indent:-2em;margin-left:4em;">Usual dosage: <b>Oral: </b>50 mg 3 times daily. <b>Note:</b> In patients who are able to consistently separate administration from food and strictly adhere to the dosing schedule, may administer 25 mg 3 times daily or 50 mg twice daily (minimum effective dose: 75 mg/day in 2 or 3 divided doses); increase dose to 50 mg 3 times daily if inadequate response to lower dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36152019','lexi-content-ref-8475943','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36152019','lexi-content-ref-8475943','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pregnant patients:</i>
<b>Oral: </b>25 mg 3 times daily; may increase to 50 mg 3 times daily if inadequate response to lower dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991863"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989159"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F9850340"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9850338"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="88572" href="/d/html/88572.html" rel="external">see "Zinc acetate: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="356294e9-9c29-43ce-b91c-44f10819a66f">Wilson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilson disease: </b>
<b>Note: </b>Dose expressed in mg of <b>elemental</b> zinc:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years to &lt;10 years: Limited data available: Oral: 25 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18506894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18506894'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Oral: 25 to 50 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18506894','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18506894','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193574"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193575"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9850326"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Neurological deterioration (uncommon)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastric irritation, increased serum amylase, increased serum lipase</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hepatic insufficiency</p></div>
<div class="block coi drugH1Div" id="F9850302"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to zinc acetate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F9850324"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Central nervous system: Neurological deterioration may occur with initial therapy as copper stores are mobilized; effects are less common when compared to chelation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Gastric irritation/upset may occur with use and particularly with the  morning dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not recommended for initial treatment of Wilson disease in symptomatic patients; may be used as maintenance therapy after patient has been stabilized on initial chelation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Therapy management: Hepatic copper levels should not be used to manage therapy  as they do not differentiate between potentially toxic free copper and safely bound copper.</p></div>
<div class="block dosfc drugH1Div" id="F21963758"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strength of Galzin capsule is expressed as elemental zinc.</p></div>
<div class="block foc drugH1Div" id="F9850352"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Galzin: 25 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Wilzin: 25 mg [DSC] [contains corn starch, fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block geq drugH1Div" id="F9882124"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322803"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Galzin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $2.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $4.54</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F9850347"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals, and at least 1 hour separated from beverages other than water. Gastric irritation is most commonly associated with morning dose; may administer morning dose between breakfast and lunch if gastric irritation occurs. Swallow capsule whole; do not chew or open.</p></div>
<div class="block admp drugH1Div" id="F52614176"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals, and 1 hour away from beverages other than water. Gastric irritation most commonly associated with morning dose; may administer 1 hour after breakfast if gastric irritation occurs. Swallow capsule whole; do not chew or open.</p></div>
<div class="block use drugH1Div" id="F9850297"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Wilson disease:</b> Maintenance treatment of Wilson disease following chelation therapy.</p></div>
<div class="block cyt drugH1Div" id="F13300235"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9922728"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Zinc Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral zinc salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral zinc salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Zinc Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Zinc Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Zinc Salts may decrease the absorption of Tetracyclines. Only a concern when both products are administered orally.  Management: Separate administration of oral tetracycline derivatives and oral zinc salts by at least 2 hours to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F9850330"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food and beverages other than water may interfere with zinc absorption. Management: Administer on empty stomach at least 1 hour before or 2 to 3 hours after meals and at least 1 hour separated from beverages other than water. Gastric irritation is most commonly associated with morning dose; may administer morning dose between breakfast and lunch if GI irritation occurs.</p></div>
<div class="block rep_considerations drugH1Div" id="F56565752"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Menstrual irregularities and infertility are associated with Wilson disease. Patients treated for Wilson disease are able to conceive and therapy should be optimized prior to pregnancy (AASLD [Schilsky 2022]).</p></div>
<div class="block pri drugH1Div" id="F9850299"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Outcome data following maternal use of zinc acetate for the treatment of Wilson disease during pregnancy are available (Brewer 2000; Mussi 2021; Pfeiffenberger 2018). Continued treatment of Wilson disease during pregnancy improves pregnancy outcomes. Appropriate doses of zinc acetate can be maintained during pregnancy. Close monitoring is recommended (AASLD [Schilsky 2022]; EASL 2012).</p></div>
<div class="block brc drugH1Div" id="F9850301"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Zinc is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of zinc in breast milk are available from a patient receiving zinc acetate 25 mg 3 times daily throughout pregnancy and following delivery for the treatment of Wilson disease. Breast milk concentrations of zinc were 10.80 mcg/mL on postpartum day 4 and 3.28 mcg/mL on postpartum day 32. Maternal serum concentrations of zinc ranged from 0.73 mcg/mL (postpartum day 3) to 1.43 mcg/mL (postpartum day 32). Authors of the study also evaluated zinc concentrations in an infant formula, which were 4.5 mcg/mL. Maternal dietary intake of zinc was not evaluated (Isagawa 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional data are available from a study of breastfeeding patients treated with zinc acetate for Wilson disease (n=6) and healthy controls (n=25). Treated patients received zinc 50 to 150 mg/day and were 15 to 118 days postpartum. Breast milk concentrations of zinc in treated patients ranged from 1.46 to 4.23 mcg/mL. In comparison, breast milk concentrations of zinc in healthy controls ranged from 0.29 to 4.62 mcg/mL. Copper concentrations were also evaluated. Breast milk concentrations of copper were 0.30 to 0.48 mcg/mL, and 0.06 to 0.60 mcg/mL in treated patients and healthy controls, respectively. Breast milk was also sampled in 1 patient 2 days after delivery treated with zinc 100 mg/day. Zinc concentrations in colostrum were 3.94 mcg/mL; copper concentrations were 0.53 mcg/mL. All mothers in this study were treated for Wilson disease prior to and during pregnancy as well as postpartum. All infants were breastfed and reported to have normal development (Kodama 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer due to the possibility of zinc-induced copper deficiency in a breastfed infant.</p></div>
<div class="block dic drugH1Div" id="F56565757"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intakes for elemental zinc: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>≥19 years of age:</b> 11 mg/day (males); 8 mg/day (females).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pregnant patients:</b> 11 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breastfeeding patients:</b> 12 mg/day.</p></div>
<div class="block mop drugH1Div" id="F9850349"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum non-ceruloplasmin bound copper (NCC), 24-hour urinary copper excretion, 24-hour urinary zinc level (target: &gt;1 to 2 mg per 24 hours) (AASLD [Schilsky 2022]); LFTs, neurologic evaluation including speech.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment efficacy:</b> 24-hour urinary copper excretion &lt;100 mcg per 24 hours; normalization of NCC (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonadherence</b>: Increased 24-hour urinary copper excretion &gt;100 mcg per 24 hours in patients previously &lt;100 mcg per 24 hours may suggest increased dietary copper intake or zinc nonadherence (AASLD [Schilsky 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Overtreatment:</b> Diminished 24-hour urinary copper excretion &lt;20 mcg per 24 hours with NCC &lt;5 mcg/dL may suggest overtreatment (AASLD [Schilsky 2022]).</p></div>
<div class="block rer drugH1Div" id="F9850346"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Non-ceruloplasmin plasma copper (free copper): &lt;20 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">Serum zinc levels: Goal &gt;125 mcg/dL (AASLD [Schilsky 2022]).</p></div>
<div class="block pha drugH1Div" id="F9850344"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Zinc induces production of the copper binding protein metallothionein in enterocytes. Copper binding within enterocytes results in an impairment of the intestinal absorption of dietary copper and reabsorption of endogenously secreted copper in saliva, bile, gastric acid.  Following enterocyte desquamation, bound copper is eliminated in the feces.</p></div>
<div class="block phk drugH1Div" id="F9850333"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Small intestine (IOM 2001); impaired with food and beverages (other than water).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Stored primarily in skeletal muscle and bone (IOM 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Albumin and alpha 1-macroglobulin (Foote 1984).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces and urine (IOM 2001).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12707705"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Galzin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nobelzin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nobelzin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Galzin | Wilzin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Wilzin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Galzin | Wilzin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zinca</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10655259">
<a name="10655259"></a>Brewer GJ, Johnson VD, Dick RD, Hedera P, Fink JK, Kluin KJ. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. <i>Hepatology</i>. 2000;31(2):364-370. doi:10.1002/hep.510310216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/10655259/pubmed" id="10655259" target="_blank">10655259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8475943">
<a name="8475943"></a>Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc XII: dose regimen requirements. <i>Am J Med Sci</i>. 1993;305(4):199-202. doi:10.1097/00000441-199304000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/8475943/pubmed" id="8475943" target="_blank">8475943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22340672">
<a name="22340672"></a>European Association for Study of Liver. EASL clinical practice guidelines: Wilson's disease. <i>J Hepatol</i>. 2012;56(3):671-685. doi:10.1016/j.jhep.2011.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/22340672/pubmed" id="22340672" target="_blank">22340672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6206098">
<a name="6206098"></a>Foote JW, Delves HT. Albumin bound and alpha 2-macroglobulin bound zinc concentrations in the sera of healthy adults. <i>J Clin Pathol</i>. 1984;37(9):1050‐1054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/6206098/pubmed" id="6206098" target="_blank">6206098</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Galzin (zinc acetate) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>. Washington, DC: National Academy Press, 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32393423">
<a name="32393423"></a>Isagawa S, Shiohira H, Hokama N, et al. Measurement of zinc concentration in blood and breast milk of a Wilson's disease patient taking zinc acetate. <i>Pharmazie</i>. 2020;75(5):177-178. doi:10.1691/ph.2020.9765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/32393423/pubmed" id="32393423" target="_blank">32393423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34222678">
<a name="34222678"></a>Kodama H, Anan Y, Izumi Y, Sato Y, Ogra Y. Copper and zinc concentrations in the breast milk of mothers undergoing treatment for Wilson's disease: a prospective study. <i>BMJ Paediatr Open</i>. 2021;5(1):e000948. doi:10.1136/bmjpo-2020-000948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/34222678/pubmed" id="34222678" target="_blank">34222678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350816">
<a name="34350816"></a>Mussi MCL, Nardelli MJ, Santos BC, et al. Pregnancy outcomes in Wilson's disease women: single- center case series. <i>Fetal Pediatr Pathol</i>. 2021:1-8. doi:10.1080/15513815.2021.1960940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/34350816/pubmed" id="34350816" target="_blank">34350816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28859232">
<a name="28859232"></a>Pfeiffenberger J, Beinhardt S, Gotthardt DN, et al. Pregnancy in Wilson's disease: management and outcome. <i>Hepatology</i>. 2018;67(4):1261-1269. doi:10.1002/hep.29490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/28859232/pubmed" id="28859232" target="_blank">28859232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18506894">
<a name="18506894"></a>Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. <i>Hepatology</i>. 2008;47(6):2089-2111. doi:10.1002/hep.22261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/18506894/pubmed" id="18506894" target="_blank">18506894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36152019">
<a name="36152019"></a>Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. Published online December 7, 2022. doi:10.1002/hep.32805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zinc-acetate-drug-information/abstract-text/36152019/pubmed" id="36152019" target="_blank">36152019</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9980 Version 186.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
